The Safety of Therapeutic Monoclonal Antibodies: Implications
for Cancer Therapy Including Immuno-Checkpoint Inhibitors

J 2016

The Safety of Therapeutic Monoclonal Antibodies: Implications for Cancer Therapy Including Immuno-Checkpoint Inhibitors

DEMLOVÁ, Regina; Dalibor VALÍK; Radka OBERMANNOVÁ a Lenka ZDRAŽILOVÁ DUBSKÁ

Základní údaje

Originální název

The Safety of Therapeutic Monoclonal Antibodies: Implications for Cancer Therapy Including Immuno-Checkpoint Inhibitors

Autoři

DEMLOVÁ, Regina; Dalibor VALÍK; Radka OBERMANNOVÁ a Lenka ZDRAŽILOVÁ DUBSKÁ

Vydání

Physiological Research, Praha, Fyziologický ústav AV ČR, 2016, 0862-8408

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.461

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/16:00093104

Organizační jednotka

Lékařská fakulta

UT WoS

000392029200005

EID Scopus

2-s2.0-85009961809

Klíčová slova anglicky

Cancer treatment; Monoclonal antibodies; Immune checkpoint inhibitors; Immune related adverse events

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 26. 4. 2017 12:56, Soňa Böhmová

Anotace

V originále

Monoclonal antibody-based treatment of cancer has been established as one of the most successful therapeutic strategies for both hematologic malignancies and solid tumors. In addition to targeting cancer antigens antibodies can also modulate immunological pathways that are critical to immune surveillance. Antibody therapy directed against several negative immunologic regulators (checkpoints) is demonstrating significant success in the past few years. Immune checkpoint inhibitors, ipilimumab, pembrolizumab and nivolumab, have shown significant clinical benefit in several malignancies and are already approved for advanced melanoma and squamous NSCLC. Based on their mechanism of action, these agents can exert toxicities that are unlike conventional cytotoxic chemotherapy, whose nature is close to autoimmune diseases - immune related adverse events (irAEs). In this review we focus on the spectrum of irAEs associated with immune checkpoint antibodies, discussing the pharmacological treatment strategy and possible clinical impact.

Návaznosti

LM2015090, projekt VaV

Název: Český národní uzel Evropské sítě infrastruktur klinického výzkumu (Akronym: CZECRIN)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CZECRIN - Český národní uzel Evropské sítě infrastruktur klinického výzkumu

Citovat

DEMLOVÁ, Regina; Dalibor VALÍK; Radka OBERMANNOVÁ a Lenka ZDRAŽILOVÁ DUBSKÁ. The Safety of Therapeutic Monoclonal Antibodies: Implications for Cancer Therapy Including Immuno-Checkpoint Inhibitors. Physiological Research. Praha: Fyziologický ústav AV ČR, 2016, roč. 65, Suppl. 4, s. "S455"-"S462", 8 s. ISSN 0862-8408.

@article{1369176,
   author = {Demlová, Regina and Valík, Dalibor and Obermannová, Radka and Zdražilová Dubská, Lenka},
   article_location = {Praha},
   article_number = {Suppl. 4},
   keywords = {Cancer treatment; Monoclonal antibodies; Immune checkpoint inhibitors; Immune related adverse events},
   language = {eng},
   issn = {0862-8408},
   journal = {Physiological Research},
   title = {The Safety of Therapeutic Monoclonal Antibodies: Implications for Cancer Therapy Including Immuno-Checkpoint Inhibitors},
   volume = {65},
   year = {2016}
}

TY  - JOUR
ID  - 1369176
AU  - Demlová, Regina - Valík, Dalibor - Obermannová, Radka - Zdražilová Dubská, Lenka
PY  - 2016
TI  - The Safety of Therapeutic Monoclonal Antibodies: Implications for Cancer Therapy Including Immuno-Checkpoint Inhibitors
JF  - Physiological Research
VL  - 65
IS  - Suppl. 4
SP  - "S455"-"S462"
EP  - "S455"-"S462"
PB  - Fyziologický ústav AV ČR
SN  - 08628408
KW  - Cancer treatment
KW  - Monoclonal antibodies
KW  - Immune checkpoint inhibitors
KW  - Immune related adverse events
N2  - Monoclonal antibody-based treatment of cancer has been established as one of the most successful therapeutic strategies for both hematologic malignancies and solid tumors. In addition to targeting cancer antigens antibodies can also modulate immunological pathways that are critical to immune surveillance. Antibody therapy directed against several negative immunologic regulators (checkpoints) is demonstrating significant success in the past few years. Immune checkpoint inhibitors, ipilimumab, pembrolizumab and nivolumab, have shown significant clinical benefit in several malignancies and are already approved for advanced melanoma and squamous NSCLC. Based on their mechanism of action, these agents can exert toxicities that are unlike conventional cytotoxic chemotherapy, whose nature is close to autoimmune diseases - immune related adverse events (irAEs). In this review we focus on the spectrum of irAEs associated with immune checkpoint antibodies, discussing the pharmacological treatment strategy and possible clinical impact.
ER  -

DEMLOVÁ, Regina; Dalibor VALÍK; Radka OBERMANNOVÁ a Lenka ZDRAŽILOVÁ DUBSKÁ. The Safety of Therapeutic Monoclonal Antibodies: Implications for Cancer Therapy Including Immuno-Checkpoint Inhibitors. \textit{Physiological Research}. Praha: Fyziologický ústav AV ČR, 2016, roč.~65, Suppl. 4, s.~''S455''-''S462'', 8 s. ISSN~0862-8408.

Přehled o publikaci